In August, a single email triggered a chain of hand-wringing and strategizing inside one of America’s largest medical technology companies: A reporter asked Boston Scientific if the biotech ...
Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...
Project Velocity Logo PVI is proud to be Certified by Great Place To Work® for the first year, less than 3 years after opening its doors as ...
Despite a more widespread shift toward product recyclability, these types of linear systems are still especially prevalent in ...
Coinciding with the launch of ‘Bharatpol’ the Central Bureau of Investigation (CBI) has, for the first time, decided to ...
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide ...
JMP Securities analyst Reni Benjamin maintained a Hold rating on Sana Biotechnology (SANA – Research Report) today. The company’s shares opened today at $1.75. Discover outperforming stocks ...
The Council of Europe implements capacity building and co-operation projects on gender equality and combating violence against women and domestic violence to provide national authorities with ...
Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York's thriving bioscience ecosystem, and outlines her vision ...
Regeneron, maker of the blockbuster ophthalmology medicine Eylea, has acquired an ocular biotech, the large biopharma confirmed to Endpoints News on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback